Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 223

1.

CD4+ T-cell counts and plasma HIV-1 RNA levels beyond 5 years of highly active antiretroviral therapy.

Li X, Margolick JB, Jamieson BD, Rinaldo CR, Phair JP, Jacobson LP.

J Acquir Immune Defic Syndr. 2011 Aug 15;57(5):421-8. doi: 10.1097/QAI.0b013e31821e9f21.

2.

Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy.

Hunt PW, Deeks SG, Rodriguez B, Valdez H, Shade SB, Abrams DI, Kitahata MM, Krone M, Neilands TB, Brand RJ, Lederman MM, Martin JN.

AIDS. 2003 Sep 5;17(13):1907-15.

PMID:
12960823
3.
4.

Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.

Kaufmann GR, Bloch M, Zaunders JJ, Smith D, Cooper DA.

AIDS. 2000 May 26;14(8):959-69.

PMID:
10853977
5.

The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.

Anastos K, Barrón Y, Cohen MH, Greenblatt RM, Minkoff H, Levine A, Young M, Gange SJ.

Ann Intern Med. 2004 Feb 17;140(4):256-64.

PMID:
14970148
6.

A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.

Hecht FM, Wang L, Collier A, Little S, Markowitz M, Margolick J, Kilby JM, Daar E, Conway B, Holte S; AIEDRP Network.

J Infect Dis. 2006 Sep 15;194(6):725-33. Epub 2006 Aug 15.

PMID:
16941337
7.

The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.

He L, Pan X, Dou Z, Huang P, Zhou X, Peng Z, Zheng J, Zhang J, Yang J, Xu Y, Jiang J, Chen L, Jiang J, Wang N.

PLoS One. 2016 Feb 22;11(2):e0148915. doi: 10.1371/journal.pone.0148915. eCollection 2016.

8.

Rates and determinants of virologic and immunological response to HAART resumption after treatment interruption in HIV-1 clinical practice.

Touloumi G, Pantazis N, Stirnadel HA, Walker AS, Boufassa F, Vanhems P, Porter K; CASCADE Collaboration.

J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):492-8. doi: 10.1097/QAI.0b013e318186ead2.

PMID:
18989233
9.

Predictors of clinical progression among HIV-1-positive patients starting HAART with CD4+ T-cell counts > or =200 cells/mm3.

Lapadula G, Torti C, Maggiolo F, Casari S, Suter F, Minoli L, Pezzoli C, Di Pietro M, Migliorino G, Ouiros-Roldan E, Ladisa N, Sighinolfi L, Costarelli S, Carosi G; Italian MASTER Cohort.

Antivir Ther. 2007;12(6):941-7.

PMID:
17926648
10.

The CD4 slope can be a predictor of immunologic recovery in advanced HIV patients: a case-control study.

Kim KH, Yi J, Lee SH.

Korean J Intern Med. 2015 Sep;30(5):705-13. doi: 10.3904/kjim.2015.30.5.705. Epub 2015 Aug 27.

11.

Association of CD4+ T-lymphocyte counts and new thymic emigrants in HIV-infected children during successful highly active antiretroviral therapy.

Saitoh A, Singh KK, Sandall S, Powell CA, Fenton T, Fletcher CV, Hsia K, Spector SA.

J Allergy Clin Immunol. 2006 Apr;117(4):909-15.

12.

Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.

Smith CJ, Sabin CA, Youle MS, Kinloch-de Loes S, Lampe FC, Madge S, Cropley I, Johnson MA, Phillips AN.

J Infect Dis. 2004 Nov 15;190(10):1860-8. Epub 2004 Oct 8.

PMID:
15499544
13.

CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.

Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M; Swiss HIV Cohort Study Group.

Arch Intern Med. 2003 Oct 13;163(18):2187-95.

PMID:
14557216
14.

Evaluation of the effectiveness of highly active antiretroviral therapy in persons with human immunodeficiency virus using biomarker-based equivalence of disease progression.

Jacobson LP, Li R, Phair J, Margolick JB, Rinaldo CR, Detels R, Muñoz A.

Am J Epidemiol. 2002 Apr 15;155(8):760-70.

PMID:
11943695
15.

Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.

Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, Montaner JS.

JAMA. 2001 Nov 28;286(20):2568-77.

PMID:
11722271
16.
17.

HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy.

Sterling TR, Chaisson RE, Moore RD.

AIDS. 2001 Nov 23;15(17):2251-7.

PMID:
11698698
18.

Early postseroconversion CD4 cell counts independently predict CD4 cell count recovery in HIV-1-postive subjects receiving antiretroviral therapy.

Kulkarni H, Okulicz JF, Grandits G, Crum-Cianflone NF, Landrum ML, Hale B, Wortmann G, Tramont E, Polis M, Dolan M, Lifson AR, Agan BK, Ahuja SK, Marconi VC.

J Acquir Immune Defic Syndr. 2011 Aug 15;57(5):387-95. doi: 10.1097/QAI.0b013e3182219113.

19.

Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users.

Tarwater PM, Gallant JE, Mellors JW, Gore ME, Phair JP, Detels R, Margolick JB, Muñoz A.

AIDS. 2004 Dec 3;18(18):2419-23.

PMID:
15622318
20.

Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.

Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD; HepaI.Co.N.A. Study Group; Italian Cohort Naive for Antiretrovirals Study Group.

Clin Infect Dis. 2005 Jun 15;40(12):e101-9. Epub 2005 May 5.

PMID:
15909251

Supplemental Content

Support Center